Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis a vaccine

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages e85-e91

  Van Herck, Koen ^a,b   Hens, Annick ^a   De Coster, Ilse ^a   Vertruyen, André ^c   Tolboom, Jeroen ^d   Sarnecki, Michal ^d   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Sint Vincentius   (Belgium)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

hepatitis A; long term protection; pediatric; virosomes

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; VIROSOME VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; FEMALE; FOLLOW UP; GENDER; HEPATITIS A; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINATION; BLOOD; CLINICAL TRIAL; IMMUNOASSAY; IMMUNOLOGY; INFANT; LONGITUDINAL STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROCEDURES; TIME FACTOR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNOASSAY; INFANT; LONGITUDINAL STUDIES; TIME FACTORS; VACCINATION; VACCINES, VIROSOME;

EID: 84937640646     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000616     Document Type: Article

References (41)

1. World Health Organization (WHO). WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec. 2012;87:261-276.
2. Koff RS. Hepatitis A. Lancet. 1998;351:1643-1649.
3. Just M, Berger R, Dreschsler H, et al. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine. 1992;10:737-739.
4. Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet. 1994;343:322-324.
5. Holzer BR, Hatz C, Schmidt-Sissolak D, et al. Immunogenicity and adverse effects of inactivated virosome versus alum-Adsorbed hepatitis A vaccine: A randomized controlled trial. Vaccine. 1996;14:982-986.
6. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine. 1997;15:1209-1213.
7. Bovier PA, Althaus B, Glueck R, et al. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med. 1999;6:228-233.
8. Bovier PA, Farinelli T, Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-Adsorbed hepatitis A vaccine. Vaccine. 2005;23:2424-2429.
9. Bovier PA, Bock J, Loutan L, et al. Long-Term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol. 2002;68:489-493.
10. Ott JJ, Irving G, Wiersma ST. Long-Term protective effects of hepatitis A vaccines. A systematic review. Vaccine. 2012;31:3-11.
11. Van Damme P, Banatvala J, Fay O, et al.; International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? Lancet. 2003;362:1065-1071.
12. Van Herck K, Crasta PD, Messier M, et al. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother. 2012;8:323-327.
13. Hens N, Habteab Ghebretinsae A, Hardt K, et al. Model based estimates of long-Term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 2014;32:1507-1513.
14. Bovier PA, Bock J, Ebengo TF, et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol. 2010;82:1629-1634.
15. Abarca K, Ibañez I, de la Fuente P, et al. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years. Vaccine. 2011;29:8855-8862.
16. Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosomeadjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: A randomized controlled trial. Pediatr Infect Dis J. 2007;26:787-793.
17. Van Der Wielen M, Vertruyen A, Froesner G, et al. Immunogenicity and safety of a pediatric dose of a virosome-Adjuvanted hepatitis A vaccine: A controlled trial in children aged 1-16 years. Pediatr Infect Dis J. 2007;26:705-710.
18. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1-23.
19. Lopez EL, Contrini MM, Mistchenko A, et al. Long-Term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J. 2010;29:568-570.
20. Raczniak GA, Bulkow LR, Bruce MG, et al. Long-Term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis. 2013;207:493-496.
21. Bian GL, Ma R, Dong HJ, et al. Long-Term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine. 2010;28:4798-4801.
22. Raczniak GA, Thomas TK, Bulkow LR, et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine. 2013;31:2152-2155.
23. Van Damme P, Leroux-Roels G, Law B, et al. Long-Term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol. 2001;65:6-13.
24. van Damme P, Kafeja F, Van Der Wielen M, et al. Long-Term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age. Pediatr Infect Dis J. 2011;30:703-705.
25. Marshall H, Nolan T, Diez Domingo J, et al. Long-Term (5-year) antibody persistence following two-And three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Vaccine. 2010;28:4411-4415.
26. Burgess MA, McIntyre PB, Hellard M, et al. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010;28:2222-2226.
27. Fan PC, Chang MH, Lee PI, et al. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine. 1998;16:232-235.
28. Hammitt LL, Bulkow L, Hennessy TW, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 2008;198:1776-1782.
29. Byrd KK, Bruden DL, Bruce MG, et al. Long-Term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years. J Ped Infect Dis. 2010;5:321-327.
30. Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J. 2003;22:354-359.
31. Chan CY, Lee SD, Yu MI, et al. Long-Term follow-up of hepatitis A vaccination in children. Vaccine. 1999;17:369-372.
32. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol. 1996;49:235-241.
33. Dagan R, Greenberg D, Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine. 2005;23:5144-5148.
34. Siegrist CA. Vaccine immunology [WHO web site]. Available at: http:// www.who.int/immunization/documents/Elsevier-Vaccine-immunology. pdf. Accessed November 13, 2013.
35. Pihlgren M, Friedli M, Tougne C, et al. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol. 2006;176:165-172.
36. Pihlgren M, Schallert N, Tougne C, et al. Delayed and deficient establishment of the long-Term bone marrow plasma cell pool during early life. Eur J Immunol. 2001;31:939-946.
37. Ambrosch F, Finkel B, Herzog C, et al. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection. 2004;32:149-152.
38. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26:3551-3555.
39. Lim J, Song YJ, Park WS, et al. The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults. Yonsei Med J. 2014;55:126-131.
40. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun. 2012;38:J282-J291.
41. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays. 2012;34: 1050-1059.